Loading...
Market
How will American pharmaceutical companies respond to scrutiny over their ties with the Chinese military by June 2025?
2
Resolution / Starting Odds
Defend their actions • 25%
Announce changes to policies • 25%
Terminate collaborations • 25%
No official response • 25%
Official statements from the companies or credible news sources
Story
US Lawmakers Probe Pharma Ties to Chinese Military in Xinjiang Trials Over Decade
Aug 20, 2024, 03:44 PM
A bipartisan group of U.S. House lawmakers is calling for an investigation into American pharmaceutical companies that have reportedly conducted clinical trials in collaboration with the Chinese military. The lawmakers have raised concerns about the involvement of Chinese hospitals in Xinjiang in these trials, which have been ongoing for over a decade. The House committee has revealed that hundreds of such trials were conducted, prompting the lawmakers to seek answers from the U.S. Food and Drug Administration (FDA). The move comes amid broader scrutiny of U.S. companies' ties with China, particularly in sensitive areas such as biopharmaceutical research.
View original story
Similar markets
Stockpiling restricted items • 25%
Developing domestic alternatives • 25%
Seeking international partnerships • 25%
Legal action against US • 25%
New Legislation Introduced • 25%
Existing Legislation Amended • 25%
No Action Taken • 25%
Other • 25%
Reimpose sanctions on ViaSat • 25%
Impose sanctions on another US defense company • 25%
Announce new trade agreements with US defense companies • 25%
No significant action • 25%
More companies added • 25%
Companies removed • 25%
No changes to the list • 25%
Both additions and removals • 25%
Additional bilateral agreements with China • 25%
Increased domestic enforcement and regulation • 25%
No significant policy changes • 25%
Other responses (e.g., public health initiatives, international cooperation) • 25%
New sanctions by the US on China • 25%
New sanctions by China on US defense companies • 25%
New trade agreements involving defense companies • 25%
No significant action • 25%
Relocate production • 25%
Absorb costs • 25%
Increase prices • 25%
Other • 25%
Support the ban • 25%
Oppose the ban • 25%
Remain neutral • 25%
Seek exemptions • 25%
Retaliatory sanctions • 25%
Formal complaint to WTO • 25%
Diplomatic negotiations • 25%
No significant action • 25%
Opposition • 25%
Support • 25%
Neutral • 25%
No official statement • 25%
Accept Apology • 25%
Demand Further Action • 25%
Sanctions/Retaliation • 25%
No Official Response • 25%